The recent identification of immunodeficient patients lacking ARPC1B (18–22) provides an opportunity to examine the role of Arp2/3 in CTLs, the contribution of CTLs to the immunodeficiency, and the molecular basis of the disease. This evidence concerns the gene ACTR2 and immunodeficiency disease.